8x8 To Present At 15th Annual Needham Growth Conference On January 15

8x8, Inc. (Nasdaq: EGHT), provider of innovative cloud communications and computing solutions, today announced that Chairman and CEO Bryan Martin and CFO Dan Weirich will present at the 15th Annual Needham Growth Conference at the New York Palace Hotel in New York on Tuesday, Jan. 15, 2013 at 2:10 p.m. ET.

A copy of the presentation will be available on the Investor Relations section of 8x8’s corporate website at http://investors.8x8.com. For automatic “e-mail alerts” regarding 8x8 news, events, and new investor materials on the website, investors can subscribe at http://investors.8x8.com/alerts.cfm.

For more information about the conference or to schedule a one-on-one meeting with 8x8 management, please contact your Needham representative.

About 8x8, Inc.

8x8 Inc. (NASDAQ: EGHT) empowers business conversations for more than 30,000 small and medium sized businesses with cloud communications services that include hosted PBX telephony, unified communications, contact center and video conferencing solutions. In 2012, the company was recognized in the “Leaders” quadrant of Gartner’s 2012 Magic Quadrant for Unified Communications as a Service and was named No. 1 Provider of Hosted IP Telephony by Frost & Sullivan. 8x8 has been delivering business communications services since 2004 and has garnered a reputation for technical excellence and outstanding reliability. For additional information, visit www.8x8.com, or connect with 8x8 on Facebook and Twitter.

Copyright Business Wire 2010

If you liked this article you might like

My Market Scans are Unimpressive

My Market Scans are Unimpressive

8x8 (EGHT) Stock Rises on Q1 Earnings Beat

8x8 (EGHT) Stock Rises on Q1 Earnings Beat

8x8 (EGHT): Today's Weak On High Volume Stock

8x8 (EGHT): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

'Mad Money' Lightning Round: Buy, Buy, Buy Seres Therapeutics

'Mad Money' Lightning Round: Buy, Buy, Buy Seres Therapeutics